Synthesis method of cephalosporin intermediate YGH

Through the reaction routes of acylation, oxidation, esterification and isomerization, the cephalosporin intermediate YGH was successfully synthesized, which solved the problem of lack of synthesis methods in the existing technology, achieved process simplification and product quality improvement, and ensured the feasibility of production and application Sex and medication safety.

CN119019420APending Publication Date: 2024-11-26GUANGDONG LIGUO PHARMACY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411109316.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The lack of mature cephalosporin intermediate YGH in the prior art has led to difficulties in production applications.

Method used

Using 6-APA as the starting material, through the reaction route of acylation, oxidation, esterification and isomerization, the specific steps include reaction with p-methylbenzoyl chloride, oxidation of peracetic acid, esterification with dibenzene diazomethane and The isomerization reaction of organic base and trimethylchlorosilane yields the oxycefos intermediate YGH.

Benefits of technology

It has achieved shortening the synthesis process route, reducing harsh conditions, facilitating production and application, reducing the generation of by-products, improving product quality and stability, and ensuring the safety of drug use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019420A_ABST
    Figure CN119019420A_ABST
Patent Text Reader

Abstract

The invention discloses a synthesis method of a cephalosporin intermediate YGH, and belongs to the technical field of chemical drugs. 6-aminopenicillanic acid (6-APA) is adopted as an initial raw material, and the final product YGH is obtained through acylation, oxidation, esterification and isomerization. The whole reaction process is short in synthetic process route, high in yield, high in purity, low in impurity content and easy to separate, and the product quality and stability can be effectively improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical medicines, and particularly relates to a method for synthesizing a cephalosporin intermediate YGH. Background Art

[0002] Cephalosporin intermediate YGH is one of the most important intermediates for the synthesis of fluoxetine sodium and latamoxetine sodium.

[0003] Fluoxetine sodium is an oxacephalosporin antibiotic developed and marketed by Shionogi Pharmaceutical Co., Ltd. in Japan in 1988. The finished product is used as an injection in the form of sodium salt. It is very stable to beta-lactamase, and its antibacterial spectrum is similar to other third-generation cephalosporins, mainly including Staphylococcus, Streptococcus (except Enterococcus), Streptococcus pneumoniae, Peptostreptococcus, Catarrhalis, Neisseria gonorrhoeae, Escherichia coli, Klebsiella, Proteus, Haemophilus influenzae, and Bacteroides.

[0004] Latamoxef Sodium is an oxycephalosporin antibiotic developed by Shionogi Pharmaceutical Co., Ltd. of Japan. It was first launched in Germany in 1981 and has good antibacterial effects on a variety of Gram-negative bacteria. Escherichia coli, influenza bacillus, Klebsiella, various types of Proteus, Enterobacter, Citrobacter, Serratia, etc. are highly sensitive to this product. It also has good antibacterial effects on anaerobic bacteria (Bacteroides), which is better than other first, second and third generation cephalosporins. This product has strong resistance to β-lactamase and low drug resistance. This product has poor effects on Pseudomonas aeruginosa and Acinetobacter. Its effect on Gram-positive bacteria such as Staphylococcus aureus and pneumococcus is weaker than that of cephalothin, cefazolin and penicillin. It is used for pneumonia, tracheitis, pleurisy, skin and soft tissue infections, bone and joint, five sense organs, wounds and other infections caused by the above-mentioned sensitive bacteria. It can also be used for sepsis and meningitis, and has good effects on lower respiratory tract infections, abdominal infections, biliary tract infections, and urogenital system infections.

[0005] Currently, there are no patents or literature reports specifically for the oxycephalosporin intermediate YGH. There are few synthesis methods involved in patents or literature reports, and there is a lack of mature process technology that can be used in production applications in the synthesis process technology. Summary of the invention

[0006] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a method for synthesizing a cephalosporin intermediate YGH, using 6-APA (6-aminopenicillanic acid) as a starting material and undergoing acylation, oxidation, esterification, and isomerization to obtain the final product YGH.

[0007] To achieve the above object, the present invention discloses the following technical solutions:

[0008] The invention provides a method for synthesizing a cephalosporin intermediate YGH. The main synthetic route is: 6-APA is reacted with p-methylbenzoyl chloride to obtain an acylate, which is then oxidized to sulfoxide using peracetic acid, esterified, and isomerized to obtain an oxycephalosporin sodium intermediate YGH.

[0009] The specific synthesis steps are as follows:

[0010] Acylation and oxidation part:

[0011] 6-APA is used as the starting material, and reacts with p-methylbenzoyl chloride to protect the amino group to obtain an acylate; under the action of peracetic acid, the sulfur atom of the acylate is oxidized to sulfoxide to obtain an oxide. The specific operation steps are as follows:

[0012] S1 Stir and dissolve purified water, acetone and sodium carbonate for ≥15min;

[0013] S2: When the temperature of the product in S1 drops to 15-20°C, add 6-APA and stir for ≥1h;

[0014] S3: When the temperature of the product in S2 drops to ≤0°C, add the acylating agent dropwise and stir for ≥1h;

[0015] S4: adding an oxidant to the product of S3 for a reaction of ≥2h, wherein the oxidant is added at a mass ratio of acylate to oxidant of 1:0.9-0.95, that is, the oxidant is added at a mass ratio of 6-APA to oxidant of 1.4-1.5:0.9-0.95;

[0016] S5 adjusts the pH of the product of S4 to ≤ 2.0 using a pH adjuster, then extracts using an extractant, distills under reduced pressure, washes, and dries.

[0017] Esterification and isomerization part:

[0018] The oxidation product is used as a raw material, the oxide reacts with diphenyldiazomethane, and the carboxyl group is protected to obtain an ester; the ester is isomerized under the action of an organic base and trimethylsilyl chloride to obtain an isomer.

[0019] The specific steps are as follows:

[0020] S6. Add the S5 product and the protective agent into the container and stir;

[0021] S7. Pour the product of S6 into ice water, stir, crystallize, filter, wash and dry;

[0022] S8. Add the product of S7 to a container, adjust the temperature to 0-5°C, then add an isomerizing agent to react, and raise the temperature after the reaction for ≥1h. After the temperature is raised to ≥20°C, maintain for ≥1h;

[0023] S9. Extract S8, dehydrate, concentrate, add a solvent, stir, crystallize, wash and dry.

[0024] Beneficial effects of the present invention:

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] 1. Currently, no research specifically targeting the synthesis process technology of this product has been found. The purpose of this invention is to develop a new synthesis process for the cephalosporin intermediate YGH.

[0027] 2. The process synthesis method of the present invention focuses on adopting new reaction routes and new raw materials to shorten the synthesis process route, reduce the harsh conditions of the synthesis process, facilitate the production and application of the new process, and further generate social and economic benefits.

[0028] 3. The use of the specific combination and process of the present invention can reduce the generation of by-products, improve product quality and stability, and ensure the safety of patient medication. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 Chromatogram of the final product YGH

[0030] Figure 2 NMR of the final product YGH DETAILED DESCRIPTION

[0031] In order to better understand the present invention, the present invention is further described below in conjunction with specific examples, wherein the terms used in the examples are for describing specific embodiments and do not constitute limitations on the scope of protection of the present invention.

[0032] The reagents used in the present invention were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0033] 1. Acylation part synthesis, which comprises the following steps:

[0034] In a reaction flask, add purified water, acetone, and sodium carbonate, stir and dissolve for t1 minute, cool the solution to T1, add 6-APA, and stir for t2 hours to obtain a white turbid solution. Continue to cool the solution to T2, and drop p-methylbenzoyl chloride into the solution within 9 minutes. After the dropwise addition is complete, continue to stir and react for t3 hours. Detect by HPLC that the 6-APA residue is less than 0.5%, and the acylation reaction is completed to obtain the acylate.

[0035] The specific preparation parameters are shown in Table 1.

[0036] Table 1

[0037]

[0038]

[0039] The oxidation part is synthesized, which comprises the following steps:

[0040] After the acylation is completed, peracetic acid is added dropwise at 0°C within 5 minutes. After the addition is completed, the reaction is maintained at 0°C with stirring for t1 hour. After the reaction is completed, HCL is added dropwise to adjust the pH to turn into a yellow-green solution, which is extracted with 600ml of ethyl acetate and separated into layers (the organic phase is yellow-green and the aqueous phase is light yellow). The aqueous layer is extracted with 400ml of ethyl acetate again, separated into layers, and the two organic phases are combined. The water is removed with anhydrous sodium sulfate, and the crystals are distilled to dryness under reduced pressure. The crystals are soaked and washed with 40ml of ethyl acetate, filtered, and washed again with 40ml of ethyl acetate three times. The oxide is dried in vacuo at 30°C to obtain the oxide.

[0041] The specific preparation parameters are shown in Table 2.

[0042] Table 2

[0043]

[0044] The esterification part is synthesized, which comprises the following steps:

[0045] In a 1000ml dry reaction bottle closed system, evacuate and replace with nitrogen three times, then add the oxide and diphenyldiazomethane to react, and after the reaction is completed, pour the reaction solution into a reaction bottle filled with 2100ml ice water and stir for full crystallization for 30 minutes. Filter by suction, wash the solid material with 200ml 0-2℃ 0.1N HCL solution and 200ml ice water, then wash with 200ml 0-2℃ 1:1 methanol-water solution, and dry in vacuum at 35℃ to obtain an ester.

[0046] The specific preparation parameters are shown in Table 3.

[0047] Table 3

[0048]

[0049] The isomerization part is synthesized, which comprises the following steps:

[0050] Under nitrogen protection, add the esterified product to a dry 250ml reaction bottle, add 41ml dichloromethane and 20.5ml triethylamine, and cool the reaction solution to 0-5°C. Add trimethylchlorosilane to the reaction solution, stir and react at 5°C for 1 hour, heat to 20°C after the reaction, maintain the temperature at 20°C and continue to react for 1 hour (during which the esterified product residue is less than 0.5% by HPLC sampling every 15 minutes). After the reaction is completed, transfer to a 1000ml reaction bottle, dilute with 300ml ethyl acetate, extract twice with 150ml 0.5N HCl, and extract once with 150ml saturated brine. Dehydrate the organic phase with anhydrous sodium sulfate, concentrate in vacuo, add 60mL solvent and stir to fully crystallize for 30 minutes. Filter and vacuum dry to obtain the final product YGH.

[0051] The specific preparation parameters are shown in Table 4.

[0052] Table 4

[0053]

[0054]

[0055] Yield result analysis:

[0056] Table 5

[0057] Experimental Group Yield / % Example 1 70.3 Example 2 75.4 Example 3 72.2 Example 4 80.9 Example 5 87.2 Example 6 84.7 Example 7 59.2 Example 8 62.5 Example 9 57.2 Example 10 75.4 Embodiment 11 78.3 Example 12 76.7 Comparative Example 1 55.4 Comparative Example 2 42.3 Comparative Example 3 61.1 Comparative Example 4 41.5 Comparative Example 5 32.6 Comparative Example 6 31.2 Comparative Example 7 60.3 Comparative Example 8 62.4 Comparative Example 9 55.7

[0058] According to Table 5, by comparing Examples 1-3 with Comparative Examples 1-3, it can be seen that the yield of the acylation part can be significantly improved when the specific combination and specific ratio of the present invention are used.

[0059] By comparing Example 4-6 with Comparative Example 4-5, it can be seen that the yield of the oxidation part can be significantly improved when the specific combination and specific ratio of the present invention are used.

[0060] By comparing Examples 7-9 with Comparative Examples 6-7, it can be seen that the yield of the esterification part can be significantly improved when the specific combination and specific ratio of the present invention are used.

[0061] By comparing Examples 10-12 with Comparative Examples 8-9, it can be seen that the yield of the isomerization part can be significantly improved when the specific combination and specific ratio of the present invention are used.

[0062] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application.

Claims

1. A method for synthesizing a cephalosporin intermediate YGH, characterized in that: YGH is obtained by using 6-aminopenicillanic acid (6-APA) as a starting material through acylation reaction, oxidation reaction, esterification reaction, and isomerization reaction. The structural formula of YGH is shown below: S1 Stir and dissolve water, acetone and sodium carbonate for ≥15min; S2: When the temperature of the product in S1 drops to 15-20°C, add 6-APA and stir for ≥1h; S3: When the temperature of the product in S2 drops to ≤0°C, add the acylating agent and stir for ≥1h; S4 adds an oxidant to the product of S3, and the reaction lasts for ≥ 2h; S5: adjusting the pH of the product of S4 to ≤ 2.0 using a pH adjusting agent, then extracting using an extractant, distilling under reduced pressure, washing and drying; S6. Add the product of S5 and the protective agent into the container and stir; S7: pouring the product of S6 into water, stirring, crystallizing, filtering, washing and drying; S8: adding the product of S7 to a container, adjusting the temperature to 0-5°C, then adding an isomerizing agent to react, and heating the container after the reaction is ≥1h, and maintaining the temperature after the temperature is raised to ≥20°C for ≥1h; S9 extracts S8, dehydrates, concentrates, and then adds a solvent to stir crystallize, wash, and dry.

2. The method for synthesizing the cephalosporin intermediate YGH as claimed in claim 1, characterized in that: The mass ratio of water, acetone, sodium carbonate and 6-APA in S1 is 20:10-11:0.9-0.95:1.

43.

3. The method for synthesizing the cephalosporin intermediate YGH as claimed in claim 1, characterized in that: S3 The acylating agent is p-toluoyl chloride.

4. The method for synthesizing the cephalosporin intermediate YGH according to claim 1 or 3, characterized in that: The mass ratio of 6-APA to acylating agent in S3 is 1.43:0.5-1.

5.

5. The method for synthesizing the cephalosporin intermediate YGH as claimed in claim 1, characterized in that: The oxidant in S4 is peracetic acid; the mass ratio of 6-APA to the oxidant is 1.4-1.5:0.9-0.

95.

6. The method for synthesizing the cephalosporin intermediate YGH as claimed in claim 1, characterized in that: The pH adjusting agent in S5 is hydrochloric acid; the extracting agent used is ethyl acetate.

7. The method for synthesizing the cephalosporin intermediate YGH according to claim 1, characterized in that: The protective agent in S6 is diphenyldiazomethane, and the mass ratio of the product in S5 to the protective agent is 1:0.5-1.

8. The method for synthesizing the cephalosporin intermediate YGH as claimed in claim 1, characterized in that: The isomerizing agent in S7 is trimethylchlorosilane, and the mass ratio of the S7 product to the isomerizing agent is 1:0.1-0.

3.

9. The method for synthesizing the cephalosporin intermediate YGH according to claim 1, characterized in that: The solvent described in S9 is at least one of dichloromethane and isopropyl ether.

Citation Information

Patent Citations

  • Tazobactam synthesis method

    CN102020663A

  • Preparation method of 6alpha-amide penicillanate sulfoxide compound

    CN103183685A

  • Preparation method of tazobactam intermediate

    CN109678886A

  • Chemical intermediates

    GB1443738A

  • Process for the preparation of 7-amino-3-((Z)-1-propen-1yl)-3-cephem-4-carboxylic acid

    US5132419A